---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021352"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:28:25.311656+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive

## Summary
- Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.
- Cash $262.9M at March 31, 2024, up from $220.2M; net $63.5M raised via ATM and warrants.
- COMP360 phase 3 for TRD on track: COMP005 top-line Q4 2024, COMP006 mid-2025.
- Phase 2 PTSD open-label: 25mg single dose well tolerated; CAPS-5 reduction 29.9 pts at week 4.
- Michael Gold joins as Chief R&D Officer May 20; Trevor Mill departs as Chief Development Officer.

## SEC filing metadata
- accession: 0001628280-24-021352
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/0001628280-24-021352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/cmps-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021352
- JSON: https://secwatch.observer/filing/0001628280-24-021352.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021352.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported three months ended March 31, 2024 results: net income $35.2 million, EPS $0.55 loss per share. Guidance initiated.
  - Period: three months ended March 31, 2024
  - Net income: $35.2 million
  - EPS: $0.55 loss per share
  - Guidance: initiated
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2024, was $35.2 million, or $0.55 loss per share (including non-cash share-based compensation expense of $5.1 million), compared with $24.2 million, or $0.57 loss per share, during the same period in 2023 (including non-cash-share-based compensation expense of $4.1 million).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/0001628280-24-021352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.